BRIEF published on 06/10/2026 at 07:35, 24 days 13 hours ago Sensorion Advances SENS-601 pour la perte auditive liée au gène GJB2 Essais Cliniques Thérapie Génique Sensorion SENS-601 Perte Auditive GJB2
BRIEF published on 06/10/2026 at 07:35, 24 days 13 hours ago Sensorion Advances SENS-601 for GJB2-Related Hearing Loss Clinical Trials Gene Therapy Sensorion SENS-601 GJB2 Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 24 days 13 hours ago Sensorion Refocuses on SENS-601 for Gene Therapy Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 06/10/2026 at 07:35, 24 days 13 hours ago Sensorion se Recentre sur SENS-601 pour la Thérapie Génique Essais Cliniques Thérapie Génique Sensorion Perte Auditive SENS-601
PRESS RELEASE published on 06/10/2026 at 07:30, 24 days 13 hours ago Inside Information / Other news releases Sensorion achieves key regulatory milestones for SENS-601 addressing GJB2-related hearing loss and discontinues SENS-501. Fast Track procedure granted by ANSM in France. Clinical trials planned in Canada and U.S. IND submission targeted by 2026 Clinical Trials Gene Therapy Sensorion Regulatory Milestones GJB2-related Hearing Loss
PRESS RELEASE published on 06/10/2026 at 07:30, 24 days 13 hours ago Informations privilégiées / Autres communiqués Sensorion franchit des étapes réglementaires clés pour SENS-601 dans la perte auditive liée au gène GJB2 et le sélectionne comme principal candidat-médicament en thérapie génique Thérapie Génique Sensorion Perte Auditive SENS-601 Gène GJB2
BRIEF published on 05/18/2026 at 07:35, 1 month 17 days ago Fred Chereau nommé Directeur Général de Sensorion Direction Générale Thérapie Génique Sensorion Fred Chereau Pertes D'audition
BRIEF published on 05/18/2026 at 07:35, 1 month 17 days ago Sensorion Appoints Fred Chereau as CEO Biotechnology CEO Appointment Gene Therapy Sensorion Fred Chereau
BRIEF published on 05/18/2026 at 07:35, 1 month 17 days ago Sensorion nomme Fred Chereau au poste de PDG Biotechnologie Thérapie Génique Nomination Du PDG Sensorion Fred Chereau
BRIEF published on 05/18/2026 at 07:35, 1 month 17 days ago Fred Chereau appointed Managing Director of Sensorion Gene Therapy General Management Hearing Loss Sensory Fred Chereau
Published on 07/03/2026 at 23:00, 22 hours 16 minutes ago Eagle Plains Partner Refined Energy Announces Final Results for Winter 2026 Drill Program at Dufferin West
Published on 07/03/2026 at 21:28, 23 hours 48 minutes ago Trifecta Gold Announces Closing of $1.66 Million Private Placement
Published on 07/03/2026 at 19:30, 1 day 1 hour ago Polaris Renewable Energy Announces Q2 2026 Investor Call Details
Published on 07/03/2026 at 13:30, 1 day 7 hours ago Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation
Published on 07/04/2026 at 17:35, 3 hours 41 minutes ago Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
Published on 07/04/2026 at 11:01, 10 hours 15 minutes ago EQS-Adhoc: Continental AG: Continental AG Sells ContiTech Group Sector
Published on 07/04/2026 at 09:05, 12 hours 11 minutes ago Velo x McLaren Mastercard Formula 1® Team Relaunches Live Your Fandom to Bring Fans Closer to the Sport They Love
Published on 07/03/2026 at 19:00, 1 day 2 hours ago PATRIMOINE ET COMMERCE: BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 30 JUIN 2026
Published on 07/03/2026 at 18:55, 1 day 2 hours ago Saudia Arabia's Mabani Aljazeera Group invests in Tatu City's Jabali Towers development
Published on 07/03/2026 at 21:49, 23 hours 27 minutes ago Safran annonce la fin des négociations concernant le projet d'acquisition d’Exail Technologies.
Published on 07/03/2026 at 21:49, 23 hours 27 minutes ago Safran announces the end of negotiations regarding the contemplated acquisition of Exail Technologies.
Published on 07/03/2026 at 18:42, 1 day 2 hours ago Total number of voting rights and shares making up the share capital at June 30, 2026
Published on 07/03/2026 at 18:36, 1 day 2 hours ago Disclosure of transactions in own shares from July 1 to July 3, 2026
